外周血T淋巴细胞AgNOR对食管癌患者预后的分析研究  

Prognoses investigation of detecting AgNOR in peripheral blood T lymphocyte in patients with esophageal carcinoma

作　　者：戴淑琴[1] 王军业[2] 王春梅[2] 何丽容[1] 戎铁华[2] 

机构地区：[1]中山大学肿瘤防治中心华南肿瘤学国家重点实验室检验科,广东广州510060 [2]中山大学肿瘤防治中心华南肿瘤学国家重点实验室胸科,广东广州510060

出　　处：《中华肿瘤防治杂志》2006年第23期1820-1821,共2页Chinese Journal of Cancer Prevention and Treatment

基　　金：广东省自然科学基金(04300288)

摘　　要：为了研究食管癌外周血T淋巴细胞AgNOR对食管癌预后的应用价值。对179例食管癌患者资料进行回顾性分析,根据术前外周血T淋巴细胞AgNOR值分为阳性与阴性组,进行生存分析。AgNOR阳性组1、3、5年生存率分别为70.6%、42.3%和39.6%。AgNOR阴性组1、3、5年生存率分别为74.1%、39.6%和35.0%。两组生存期差异无统计学意义,P=0.817。初步研究结果提示,外周血T淋细胞AgNOR不能作为食管癌独立的预后因素。To investigate the prognoses value of AgNOR in peripheral blood T lymphocyte in esophageal carcinoma. 179 patients with esophageal neoplasm were retrospectively analysed. All pationts were divided into 2 groups （AgNOR positive group and AgNOR negtive group） according to the preoperation value of AgNOR in peripheral blood T lymphocyte. Survival analysis were used in 2 groups, 1 ,3 and 5 year survival rates were 70. 6%, 42. 3% and 39. 6% respectively in AgNOR positive group. 1, 3 and 5 year survival rates were74. 1%, 39. 6% and 35. 0% respectively in AgNOR negative group. There was no significant difference between 2 groups, P=0. 817. AgNOR value in peripheral blood T lymphocyte can＇t be considered as a independent prognosis factor in patients with esophageal carcinoma.

关 键 词：食管肿瘤/外科学 核仁组成区/AgNOR 预后 

分 类 号：R735.1[医药卫生—肿瘤]